Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheridan M Hoy

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
Clinical Drug Investigation|June 8, 2019
Rifamycin SV MMX<sup>®</sup>: A Review in the Treatment of Traveller's DiarrhoeaSheridan M Hoy
Drugs|July 23, 2016
Diclofenac Sodium Bolus Injection (Dyloject(TM)): A Review in Acute Pain ManagementSheridan M Hoy
American Journal of Clinical Dermatology|October 28, 2017
Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic DermatitisSheridan M Hoy
Drugs|February 18, 2018
Netarsudil Ophthalmic Solution 0.02%: First Global ApprovalSheridan M Hoy
Drugs|August 3, 2021
Pegcetacoplan: First ApprovalSheridan M Hoy
Drugs|August 23, 2022
Amubarvimab/Romlusevimab: First ApprovalSheridan M Hoy
CNS Drugs|May 23, 2018
Lacosamide: A Review in Focal-Onset Seizures in Patients with EpilepsySheridan M Hoy
Drugs|February 20, 2022
Tezepelumab: First ApprovalSheridan M Hoy
Drugs|September 26, 2018
Patisiran: First Global ApprovalSheridan M Hoy
Drugs|November 25, 2023
Correction: Elacestrant: First ApprovalSheridan M Hoy
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
Clinical Drug Investigation|June 8, 2019
Rifamycin SV MMX<sup>®</sup>: A Review in the Treatment of Traveller's DiarrhoeaSheridan M Hoy
Drugs|July 23, 2016
Diclofenac Sodium Bolus Injection (Dyloject(TM)): A Review in Acute Pain ManagementSheridan M Hoy
American Journal of Clinical Dermatology|October 28, 2017
Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic DermatitisSheridan M Hoy
Drugs|February 18, 2018
Netarsudil Ophthalmic Solution 0.02%: First Global ApprovalSheridan M Hoy
Drugs|August 3, 2021
Pegcetacoplan: First ApprovalSheridan M Hoy
Drugs|August 23, 2022
Amubarvimab/Romlusevimab: First ApprovalSheridan M Hoy
CNS Drugs|May 23, 2018
Lacosamide: A Review in Focal-Onset Seizures in Patients with EpilepsySheridan M Hoy
Drugs|February 20, 2022
Tezepelumab: First ApprovalSheridan M Hoy
Drugs|September 26, 2018
Patisiran: First Global ApprovalSheridan M Hoy
Drugs|November 25, 2023
Correction: Elacestrant: First ApprovalSheridan M Hoy
Pageof 14